Today's Veterinary Business

FEB 2019

Today’s Veterinary Business provides information and resources designed to help veterinarians and office management improve the financial performance of their practices, allowing them to increase the level of patient care and client service.

Issue link: https://todaysveterinarybusiness.epubxp.com/i/1079766

Contents of this Issue

Navigation

Page 36 of 71

• Reducing or eliminating clinical signs of Cushing's syndrome enhances the quality of life for both dog and owner. • Managing Cushing's syndrome with VETORYL Capsules is not only good medicine; it also contributes to the revenue to the clinic. • As with all drugs, side effects may occur. In field studies, the most common side effects reported were poor/reduced appetite, vomiting, lethargy, diarrhea, and weakness. Occasionally, more serious side effects, including severe depression, hemorrhagic diarrhea, collapse, hypoadrenocortical crisis, or adrenal necrosis/rupture may occur, and may result in death. Treat Cushing's Syndrome In Dogs with VETORYL ® (trilostane) Capsules Quick REVIEW • Cushing's syndrome is an endocrine condition, also known as hyperadrenocorticism (HAC). • Clinical signs arise due to an excess of cortisol production. Cortisol is the body's natural stress-fighting and anti-inflammatory hormone. • Some clinical signs of Cushing's syndrome may initially be overlooked because they mimic normal aging changes. These signs include, but are not limited to: Features of VETORYL Capsules: Functions: • The only FDA veterinary-approved treatment for hyperadrenocorticism, both pituitary-dependent (PDH) and adrenal-dependent (ADH). • Contains the active ingredient trilostane, which blocks the excessive production of cortisol. • Proven safety and efficacy. • Available in 10 mg, 30 mg, 60 mg, and 120 mg, providing dosing options for dogs of all sizes. • The active ingredient, trilostane, inhibits the excessive production of cortisol. This can be reversed by discontinuing treatment with trilostane. • VETORYL Capsules contain trilostane formulated/micronized for proper dissolution in the bloodstream. Compounded trilostane may vary in prescribed strength as well as dissolution characteristics (bioavailability), which can substantially compromise and complicate the management of Cushing's syndrome. 1 • Daily administration may greatly reduce the clinical signs associated with Cushing's syndrome. Sound VETORYL ® is a trademark of Dechra Ltd. ©2018 • NADA 141-291, Approved by FDA LYSODREN ® is a registered trademark of Bristol-Meyers Squibb Company New York, NY 10154 4/14/2003 1 Pharmaceutical Evaluation of Compounded Trilostane Products (Cook, et al, JAAHA 48:4, Jul/Aug 2012) For full prescribing information, see VETORYL Capsules package insert. Benefits/Risks: • Increased water intake • Pot belly • Frequent urination • Excessive panting • Muscle wasting/weakness • Hair loss • Lethargy • Recurring skin disease (esp. pyoderma) • Increased appetite • Thinning skin

Articles in this issue

Archives of this issue

view archives of Today's Veterinary Business - FEB 2019